ATNM Actinium Pharmaceuticals Inc

USD 7.45 0.00 0
Icon

Actinium Pharmaceuticals Inc (ATNM) Stock Analysis and Price Targets

COMMON STOCK | Biotechnology | NYE
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 7.45

0.00 (0.00)%

USD 0.22B

0.31M

USD 24.29(+225.98%)

N/A

Icon

ATNM

Actinium Pharmaceuticals Inc (USD)
COMMON STOCK | NYE
USD 7.45
0.00 0
Take a Tour
stockTargetAdvisor

Strong Buy

Average Analyst
Rating
stockTargetAdvisor

Strong Buy

Top Analyst
Rating
stockTargetAdvisor

Very Bearish

Stock Target Advisor
Analysis
stockTargetAdvisor

N/A

Average User
Rating

USD 0.22B

N/A

USD 7.45

Actinium Pharmaceuticals Inc (ATNM) Stock Forecast

Show ratings and price targets of :
USD 24.29
(+225.98%)

Based on the Actinium Pharmaceuticals Inc stock forecast from 5 analysts, the average analyst target price for Actinium Pharmaceuticals Inc is USD 24.29 over the next 12 months. Actinium Pharmaceuticals Inc’s average analyst rating is Strong Buy. Stock Target Advisor’s own stock analysis of Actinium Pharmaceuticals Inc is Very Bearish, which is based on 0 positive signals and 5 negative signals. At the last closing, Actinium Pharmaceuticals Inc’s stock price was USD 7.45. Actinium Pharmaceuticals Inc’s stock price has changed by +6.89% over the past week, -7.11% over the past month and +4.20% over the last year.

No recent analyst target price found for Actinium Pharmaceuticals Inc
No recent average analyst rating found for Actinium Pharmaceuticals Inc

Company Overview Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops targeted radiotherapies to deliver cancer-killing radiation to treat patients with high unmet medical needs. Its lead product candidate, Iomab-B (I-131 apamistamab) that is in a pivotal Phase III...Read More

100 Park Avenue, New York, NY, United States, 10017

49

December

USD

USA

Adjusted Closing Price for Actinium Pharmaceuticals Inc (ATNM)

Loading...

Unadjusted Closing Price for Actinium Pharmaceuticals Inc (ATNM)

Loading...

Share Trading Volume for Actinium Pharmaceuticals Inc Shares

Loading...

Compare Performance of Actinium Pharmaceuticals Inc Shares

Symbol Capital Gain Dividend Return Total Return
Loading...
Loading...

Technical Indicators for ATNM

Assets

Top Holdings

Top Sectors

Top Regions

Stocks Similar To Actinium Pharmaceuticals Inc (Sector: Biotechnology )

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
NVO
Novo Nordisk A/S 0.00 (0.00%) USD634.05B 49.43 4.92

ETFs Containing ATNM

Symbol Name ATNM's Weight Expense Ratio Price(Change) Market Cap

Frequently Asked Questions About Actinium Pharmaceuticals Inc (ATNM) Stock

Based on ratings from 5 analysts Actinium Pharmaceuticals Inc's stock is Strong Buy. Stock Target Advisor's fundamental analysis is Very Bearish. The stock has 7 buy, sell and hold ratings.

Unfortunately we do not have enough data on ATNM's stock to indicate if its a good dividend stock.

Based on targets from 5 analysts, the average taret price for ATNM is USD 24.29 over the next 12 months. The maximum analyst target price is USD 26 while the minimum anlayst target price is USD 20.

Unfortunately we do not have enough data on ATNM's stock to indicate if its overvalued.

The last closing price of ATNM's stock was USD 7.45.

The most recent market capitalization for ATNM is USD 0.22B.

Based on targets from 5 analysts, the average taret price for ATNM is projected at USD 24.29 over the next 12 months. This means that ATNM's stock price may go up by +225.98% over the next 12 months.

We can't find any ETFs which contains Actinium Pharmaceuticals Inc's stock.

As per our most recent records Actinium Pharmaceuticals Inc has 49 Employees.

Actinium Pharmaceuticals Inc's registered address is 100 Park Avenue, New York, NY, United States, 10017. You can get more information about it from Actinium Pharmaceuticals Inc's website at https://www.actiniumpharma.com.
Heading 1 Heading 2 Heading 3 Heading 4 Heading 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5
Data 1Data 2Data 3Data 4Data 5

Stock Target Advisor's Analysis

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

Icon
What to like

Icon
What not to like

Loading...